Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TSHA Taysha Gene Therapies, Inc.

Pre-Mkt 05-18 08:35:23 EDT

5.96

-0.34

-5.40%

盘前6.14

+0.18+3.08%

07:05 EDT

High6.24	Low5.81	Vol3.25M
Open6.16	D1 Closing6.30	Amplitude6.88%
Mkt Cap1.71B	Tradable Cap1.10B	Total Shares287.27M
T/O19.33M	T/O Rate1.76%	Tradable Shares185.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TSHA","market":"US","secType":"STK","nameCN":"Taysha Gene Therapies, Inc.","latestPrice":5.96,"timestamp":1778875200000,"preClose":6.3,"halted":0,"volume":3250668,"hourTrading":{"tag":"盘前","latestPrice":6.1438,"preClose":5.96,"latestTime":"07:05 EDT","volume":598,"amount":3574.680148,"timestamp":1779102359709,"change":0.1838,"changeRate":0.030839,"amplitude":0.033557},"delay":0,"changeRate":-0.05396825396825395,"floatShares":185000000,"shares":287269885,"eps":-0.377498,"marketStatus":"Pre-Mkt","change":-0.34,"latestTime":"05-18 08:35:23 EDT","open":6.16,"high":6.2386,"low":5.805,"amount":19326365.495136,"amplitude":0.068825,"askPrice":6.29,"askSize":100,"bidPrice":5.85,"bidSize":60,"shortable":3,"etf":0,"ttmEps":-0.377498,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779111000000},"marketStatusCode":1,"adr":0,"listingDate":1600920000000,"exchange":"NASDAQ","adjPreClose":5.96,"preHourTrading":{"tag":"盘前","latestPrice":6.1438,"preClose":5.96,"latestTime":"07:05 EDT","volume":598,"amount":3574.680148,"timestamp":1779102359709,"change":0.1838,"changeRate":0.030839,"amplitude":0.033557},"postHourTrading":{"tag":"盘后","latestPrice":5.8001,"preClose":5.96,"latestTime":"19:58 EDT","volume":24142,"amount":142950.971,"timestamp":1778889518854,"change":-0.1599,"changeRate":-0.026829,"amplitude":0.048641},"volumeRatio":1.4859626108257402,"impliedVol":1.57,"impliedVolPercentile":0.896},"requestUrl":"/m/hq/s/TSHA","defaultTab":"news","newsList":[{"id":"2634040371","title":"A Look At Taysha Gene Therapies (TSHA) Valuation After FDA Alignment On TSHA-102 BLA Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2634040371","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634040371?lang=en_us&edition=fundamental","pubTime":"2026-05-11 14:24","pubTimestamp":1778480661,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies (TSHA) has reaffirmed FDA alignment on the Biologics License Application pathway for TSHA-102, including pivotal trial design and the potential use of a six month interim analysis for approval.\nSee our latest analysis for Taysha Gene Therapies.\nThe reaffirmed FDA pathway comes after a run in the stock, with a 30 day share price return of 45.95% and a 1 year total shareholder return of 217.62%. This signals strong momentum despite recent earnings losses and ongoing cash...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/a-look-at-taysha-gene-therapies-tsha-valuation-after-fda-ali","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/a-look-at-taysha-gene-therapies-tsha-valuation-after-fda-ali","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4588","TSHA","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634427379","title":"Taysha Gene Therapies Ramps Up Ahead of TSHA-102 BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2634427379","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634427379?lang=en_us&edition=fundamental","pubTime":"2026-05-11 08:11","pubTimestamp":1778458267,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. (($TSHA)) has held its Q1 earnings call. Read on for the main highlights of the call. Taysha Gene Therapies’ latest ear...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-ramps-up-ahead-of-tsha-102-bla?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-ramps-up-ahead-of-tsha-102-bla?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633497123","title":"Whitney Ijem Reiterates Buy Rating and Maintains $17 Price Target on Clinical Momentum and Strong Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2633497123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633497123?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:58","pubTimestamp":1778162302,"startTime":"0","endTime":"0","summary":"Analyst Whitney Ijem of Canaccord Genuity maintained a Buy rating on Taysha Gene Therapies, retaining the price target of $17.00. Whitney Ijem has ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/whitney-ijem-reiterates-buy-rating-and-maintains-17-price-target-on-clinical-momentum-and-strong-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/whitney-ijem-reiterates-buy-rating-and-maintains-17-price-target-on-clinical-momentum-and-strong-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633340194","title":"Taysha Gene Therapies reports Q1 EPS (12c), consensus (10c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633340194","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633340194?lang=en_us&edition=fundamental","pubTime":"2026-05-07 13:59","pubTimestamp":1778133578,"startTime":"0","endTime":"0","summary":"“We continued to execute our clinical development strategy for TSHA-102 and recently reaffirmed alignment with the FDA on our pathway to a BLA fili...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/taysha-gene-therapies-reports-q1-eps-12c-consensus-10c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/taysha-gene-therapies-reports-q1-eps-12c-consensus-10c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633550811","title":"Chardan Capital Remains a Buy on Taysha Gene Therapies (TSHA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633550811","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633550811?lang=en_us&edition=fundamental","pubTime":"2026-05-07 02:55","pubTimestamp":1778093733,"startTime":"0","endTime":"0","summary":"In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Taysha Gene Therapies, with a price target of $12.00. L...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-remains-a-buy-on-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-remains-a-buy-on-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633132222","title":"Taysha Gene Therapies Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633132222","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633132222?lang=en_us&edition=fundamental","pubTime":"2026-05-06 23:27","pubTimestamp":1778081232,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies Inc reports results for the quarter ended December 31 - Earnings SummaryTaysha Gene Therapies Inc TSHA.OQ reported a quarterly adjusted loss of 8 cents per share for the quarter ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL8N41J2P7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633138489","title":"Taysha Gene Therapies Q1 net loss widens on higher R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2633138489","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633138489?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:08","pubTimestamp":1778069326,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies Q1 net loss widens on higher R&D costsOverviewU.S. gene therapy developer's net loss widened on higher R&D costsHigher expenses driven by BLA-enabling manufacturing and clinical ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL1N41J0N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633138193","title":"Taysha Gene Therapies Q1 EPS $(0.12) Misses $(0.10) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633138193","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633138193?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:06","pubTimestamp":1778069175,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent. This is a 50 percent decrease over losses of $(0.08) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52317998/taysha-gene-therapies-q1-eps-0-12-misses-0-10-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633138386","title":"BRIEF-Taysha Gene Therapies Q1 Net Income USD -42.41 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633138386","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633138386?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:00","pubTimestamp":1778068847,"startTime":"0","endTime":"0","summary":"BRIEF-Taysha Gene Therapies Q1 Net Income USD -42.41 Million\n\n\nMay 06 (Reuters) - Taysha Gene Therapies Q1 operating expenses USD 43.486 million.\n\nQ1 operating income USD -43.486 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLXD25841:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633138866","title":"Taysha Gene Therapies Q1 Operating Income USD -43.486 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633138866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633138866?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:00","pubTimestamp":1778068802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLXD25841:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633653133","title":"Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633653133","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633653133?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:00","pubTimestamp":1778068800,"startTime":"0","endTime":"0","summary":"Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recen","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288743/0/en/Taysha-Gene-Therapies-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2517655028.SGD","IT","LU2746668461.USD","BK4588","CMC","LU2362541273.HKD","BK4135","CNS","IE00BFXG1179.USD","LU0971096721.USD","LU2362540622.SGD","LU2746668974.SGD","LU2237443622.USD","LU2237443978.SGD","LU0154245673.USD","LU2362541513.USD","LU2237443895.HKD","LU2517655374.HKD","TSHA","BK4139","LU0267386448.USD","IE00BKVL7J92.USD","LU2517655291.USD","LU0154245756.USD","LU1814569148.SGD","BK4006","LU2237443549.SGD","LU1363072403.SGD","LU0170899867.USD","LU0149725797.USD","LU2237443465.HKD","LU2237443382.USD","BK4585","IE00BZ1G4Q59.USD","IE00BHPRN162.USD","IE00B1BXHZ80.USD","LU0107464264.USD","BK4134","LU0882574139.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632427076","title":"Taysha Gene Therapies grants 188,000 RSUs to five new employees under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2632427076","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632427076?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:06","pubTimestamp":1777666001,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies granted 188,000 restricted stock units to five newly hired employees on May 1, 2026.Awards were issued under Taysha 2023 Inducement Plan.RSUs vest in four equal annual installments starting on first anniversary of vesting commencement date.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL3CmlTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","SG9999014005.SGD","NDAQ","BK4585","BK4139","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014021.USD","BK4112","IE00B64PRP62.GBP","LU2210150020.SGD","TSHA","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632006642","title":"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632006642","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632006642?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:05","pubTimestamp":1777665900,"startTime":"0","endTime":"0","summary":"DALLAS, May  01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/01/3286205/0/en/Taysha-Gene-Therapies-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4135","CNS","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631519829","title":"Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6","url":"https://stock-news.laohu8.com/highlight/detail?id=2631519829","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631519829?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:00","pubTimestamp":1777464000,"startTime":"0","endTime":"0","summary":"DALLAS, April  29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3283681/0/en/Taysha-Gene-Therapies-to-Release-First-Quarter-2026-Financial-Results-and-Host-Conference-Call-and-Webcast-on-May-6.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4181","HST","BK4139","BK4588","BK4218","TSHA","CNS","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630534841","title":"Taysha Gene Therapies to present new TSHA-102 preclinical data at ASGCT annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630534841","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630534841?lang=en_us&edition=fundamental","pubTime":"2026-04-28 05:21","pubTimestamp":1777324904,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies will present new preclinical in vitro data on TSHA-102 at ASGCT Annual Meeting in Boston on May 11-15, 2026.Poster presentation scheduled for May 14, 2026, 5:00-6:30 PM ET.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL2DRfSx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014021.USD","TSHA","IE00B64PRP62.GBP","BK4585","BK4112","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4139","LU2095319765.USD","BK4588","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","NDAQ","IE00BN0W2W23.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629045063","title":"Taysha Gene Therapies announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629045063","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629045063?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:03","pubTimestamp":1776859428,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies schedules annual stockholder meeting for June 1, 2026, to be held virtually.Ballot includes election of two Class III director nominees to terms ending at 2029 annual meeting.Advisory votes cover named executive officer compensation, plus preferred frequency of future say-on-pay votes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL592pj0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627214080","title":"Unusually active option classes on open April 16th","url":"https://stock-news.laohu8.com/highlight/detail?id=2627214080","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627214080?lang=en_us&edition=fundamental","pubTime":"2026-04-16 23:12","pubTimestamp":1776352334,"startTime":"0","endTime":"0","summary":"Unusual total active option classes on open include: Taysha Gene Therapies (TSHA), Energy Vault Holdings (NRGV), New Era Energy & Digital Inc (NUAI...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-april-16th-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-april-16th-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4182","BK4139","NRGV","TSHA","BK4561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627230353","title":"U.S. Small Caps Finish Mixed As Taysha Gene Therapies Leads, BRP Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2627230353","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627230353?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:21","pubTimestamp":1776284460,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies were mixed Wednesday, as the Russell 2000 Index increased 0.3%, while the S&P Small Cap 600 Index was down 0.1%.Among companies with a market value of $1 billion to $6.7 billion, Taysha Gene Therapies Inc. was the best performer during the session, surging 27%, followed by Nexa Resources S.A., which surged 23%. D-Wave Quantum Inc. shares surged 23%, Maase Inc. surged 17%, and shares of Quantum Computing Inc. surged 16%.BRP Inc. was the biggest laggard, dropping 35%, followed by shares of Polaris Inc., which dropped 17%. Shares of Polibeli Group Ltd. dropped 16%, SolarEdge Technologies Inc. shares plunged 12%, and Intercorp Financial Services Inc. tumbled 11%.Major stock indexes in the U.S. ended Wednesday mixed as the Nasdaq Composite Index gained 1.6%. Meanwhile, the S&P 500 Index gained 0.8%, and the Dow Jones Industrial Average declined 0.1%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627284517","title":"Buy Rating on Taysha Gene Therapies Driven by Strong Leadership, Strategic Positioning, and Attractive Risk‑Reward Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2627284517","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627284517?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:16","pubTimestamp":1776255401,"startTime":"0","endTime":"0","summary":"Needham analyst Gil Blum has maintained their bullish stance on TSHA stock, giving a Buy rating on April 6. Gil Blum has given his Buy rating due t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-taysha-gene-therapies-driven-by-strong-leadership-strategic-positioning-and-attractive-risk‑reward-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-taysha-gene-therapies-driven-by-strong-leadership-strategic-positioning-and-attractive-risk‑reward-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627656404","title":"Taysha Gene Therapies President Sukumar Nagendran disposes 200,000 shares for $892,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2627656404","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627656404?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:34","pubTimestamp":1776112484,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies director, President and Head of R&D Sukumar Nagendran sold 200,000 shares on April 10, 2026 at USD 4.46.He exercised stock options for 19,021 shares on April 10, 2026 at USD 1.71.Directly held common stock position stood at 1,136,410 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL9gDwJs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Taysha Gene Therapies President Sukumar Nagendran disposes 200,000 shares for $892,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tayshagtx.com","stockEarnings":[{"period":"1week","weight":-0.1248},{"period":"1month","weight":-0.0067},{"period":"3month","weight":0.3099},{"period":"6month","weight":0.4431},{"period":"1year","weight":1.3281},{"period":"ytd","weight":0.0836}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.177745},{"month":2,"riseRate":0.5,"avgChangeRate":0.091899},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.104956},{"month":4,"riseRate":0.5,"avgChangeRate":0.079391},{"month":5,"riseRate":0.333333,"avgChangeRate":0.035237},{"month":6,"riseRate":0.2,"avgChangeRate":-0.029545},{"month":7,"riseRate":0.6,"avgChangeRate":0.019307},{"month":8,"riseRate":0.8,"avgChangeRate":0.75256},{"month":9,"riseRate":0.2,"avgChangeRate":-0.089587},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.04036},{"month":11,"riseRate":0.5,"avgChangeRate":0.137875},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.034429}],"exchange":"NASDAQ","name":"Taysha Gene Therapies, Inc.","nameEN":"Taysha Gene Therapies, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Taysha Gene Therapies, Inc.(TSHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Taysha Gene Therapies, Inc.,TSHA,Taysha Gene Therapies, Inc.股票,Taysha Gene Therapies, Inc.股票老虎,Taysha Gene Therapies, Inc.股票老虎国际,Taysha Gene Therapies, Inc.行情,Taysha Gene Therapies, Inc.股票行情,Taysha Gene Therapies, Inc.股价,Taysha Gene Therapies, Inc.股市,Taysha Gene Therapies, Inc.股票价格,Taysha Gene Therapies, Inc.股票交易,Taysha Gene Therapies, Inc.股票购买,Taysha Gene Therapies, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Taysha Gene Therapies, Inc.(TSHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}